US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
DE69731836T2
(en)
*
|
1996-07-23 |
2005-12-01 |
Pangenetics B.V. |
INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
WO2000066155A1
(en)
|
1999-04-30 |
2000-11-09 |
La Jolla Institute For Allergy And Immunology |
Methods for preventing reactivation of latent virus and controlling virus replication
|
JP2002544174A
(en)
|
1999-05-07 |
2002-12-24 |
ジェネンテック・インコーポレーテッド |
Treatment of autoimmune diseases using antagonists that bind to B cell surface markers
|
US7312318B2
(en)
*
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
JP4286483B2
(en)
*
|
1999-06-09 |
2009-07-01 |
イムノメディクス, インコーポレイテッド |
Immunotherapy for autoimmune diseases using antibodies targeting B cells
|
AU6929100A
(en)
*
|
1999-08-23 |
2001-03-19 |
Biocrystal Limited |
Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
|
AU1072701A
(en)
*
|
1999-10-04 |
2001-05-10 |
Chiron Corporation |
Cd40 antagonist for treating psoriasis
|
EP1839674A1
(en)
*
|
1999-10-04 |
2007-10-03 |
Novartis Vaccines and Diagnostics, Inc. |
CD40 antagonist for treating psoriasis
|
US6849425B1
(en)
*
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
AU1590201A
(en)
*
|
1999-11-09 |
2001-06-06 |
Chiron Corporation |
Compositions and methods for treating autoimmune diseases and transplant rejections
|
GB0001448D0
(en)
|
2000-01-21 |
2000-03-08 |
Novartis Ag |
Organic compounds
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
CA2406961A1
(en)
*
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
US20030059427A1
(en)
*
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
MXPA03002262A
(en)
*
|
2000-09-18 |
2003-10-15 |
Idec Pharma Corp |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination.
|
AU2002250352C1
(en)
*
|
2001-04-02 |
2009-04-30 |
Genentech, Inc. |
Combination therapy
|
ATE374214T1
(en)
*
|
2001-04-27 |
2007-10-15 |
Kirin Brewery |
MONOCLONAL ANTI-CD-40 ANTIBODY
|
WO2003024480A2
(en)
*
|
2001-09-14 |
2003-03-27 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
AR039067A1
(en)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
ANTIBODIES FOR CD40
|
EP1455812A4
(en)
*
|
2001-11-26 |
2006-03-22 |
Chiron Corp |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
AU2003300842A1
(en)
*
|
2002-12-09 |
2004-06-30 |
Tolerrx, Inc. |
Inducing tolerance in primates
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
ATE447412T1
(en)
*
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES AND METHODS OF USE
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US7674884B2
(en)
*
|
2003-12-10 |
2010-03-09 |
Novimmune S.A. |
Neutralizing antibodies and methods of use thereof
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
CN1980957A
(en)
|
2004-03-23 |
2007-06-13 |
比奥根艾迪克Ma公司 |
Receptor coupling agents and therapeutic uses thereof
|
EP1853630A1
(en)
*
|
2004-10-22 |
2007-11-14 |
Applied Molecular Evolution Inc. |
Methods of optimizing antibody variable region binding affinity
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
ES2634260T3
(en)
*
|
2005-04-06 |
2017-09-27 |
Bristol-Myers Squibb Company |
Methods for treating immune disorders associated with graft transplantation with soluble mutant CTLA4 molecules
|
DK1889065T3
(en)
|
2005-05-18 |
2013-09-02 |
Xoma Technology Ltd |
METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES WITH AN AUTO-IMMUNE AND / OR INFLAMMATION COMPONENT
|
ATE485057T1
(en)
*
|
2005-05-26 |
2010-11-15 |
Seattle Genetics Inc |
HUMANIZED ANTIBODIES AGAINST CD40 AND METHOD FOR THEIR USE
|
US7668387B2
(en)
*
|
2005-06-20 |
2010-02-23 |
Intel Corporation |
Selective local transient improvement and peaking for video sharpness enhancement
|
EP1912675B1
(en)
*
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
US20080131914A1
(en)
*
|
2005-09-14 |
2008-06-05 |
Ahearn Joseph M |
Assessing risk of cerebrovascular thrombosis by measuring c4d
|
US20070202549A1
(en)
*
|
2005-09-14 |
2007-08-30 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
|
WO2007033369A2
(en)
*
|
2005-09-14 |
2007-03-22 |
University Of Pittsburgh |
Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
|
KR20080073725A
(en)
|
2005-11-01 |
2008-08-11 |
노파르티스 아게 |
Uses of anti-cd40 antibodies
|
CN101426817B
(en)
|
2006-04-21 |
2013-07-10 |
诺华有限公司 |
Antagonist anti-cd40 antibody pharmaceutical compositions
|
CA2652599C
(en)
|
2006-05-03 |
2019-09-24 |
Ross Kedl |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
WO2008019346A2
(en)
*
|
2006-08-04 |
2008-02-14 |
Baxter International Inc. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
US20090074711A1
(en)
*
|
2006-09-07 |
2009-03-19 |
University Of Southhampton |
Human therapies using chimeric agonistic anti-human cd40 antibody
|
SG183044A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugatesand methods of use
|
EP2502937B1
(en)
|
2007-07-16 |
2016-04-06 |
Genentech, Inc. |
Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use
|
CA2713504A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
WO2010104748A2
(en)
|
2009-03-10 |
2010-09-16 |
Baylor Research Institute |
Antigen presenting cell targeted anti-viral vaccines
|
ES2635080T3
(en)
*
|
2009-03-10 |
2017-10-02 |
Baylor Research Institute |
Cancer vaccines targeting antigen presenting cells
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
|
BR112012024713B1
(en)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
humanized antibody, its uses and pharmaceutical composition that comprises it
|
AU2011252851B2
(en)
*
|
2010-05-14 |
2016-10-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to CD47
|
AR083847A1
(en)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
FC VARIANTS (CONSTANT FRAGMENT) SILENCERS OF ANTI-CD40 ANTIBODIES
|
CA2852056C
(en)
|
2011-03-11 |
2021-08-10 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
KR101734614B1
(en)
|
2011-04-21 |
2017-05-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibody polypeptides that antagonize cd40
|
EP3508500A1
(en)
|
2011-04-29 |
2019-07-10 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
PE20141478A1
(en)
|
2011-10-13 |
2014-10-23 |
Bristol Myers Squibb Co |
POLYPEPTIDES OF ANTIBODIES THAT ANTAGONIZE CD40L
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
EP3925977A1
(en)
|
2012-10-30 |
2021-12-22 |
Apexigen, Inc. |
Anti-cd40 antibodies and methods of use
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
KR20230078823A
(en)
|
2012-12-13 |
2023-06-02 |
이뮤노메딕스, 인코오포레이티드 |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2015106281A1
(en)
|
2014-01-13 |
2015-07-16 |
Baylor Research Institute |
Novel vaccines against hpv and hpv-related diseases
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
EP3113796A1
(en)
|
2014-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
CN106573981A
(en)
|
2014-08-12 |
2017-04-19 |
鳄鱼生物科学公司 |
Combination therapies with anti CD40 antibodies
|
MX2017003546A
(en)
*
|
2014-09-16 |
2017-08-14 |
Ubi Ip Holdings |
Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition.
|
DK3262071T3
(en)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Method of using anti-CD79b immune conjugates
|
PL3212230T3
(en)
|
2014-10-29 |
2021-07-26 |
Seagen Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
EP3229586A4
(en)
|
2014-12-10 |
2018-10-24 |
Regents of the University of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
JP6746845B2
(en)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells
|
KR102661078B1
(en)
*
|
2015-05-29 |
2024-05-23 |
애브비 인코포레이티드 |
Anti-CD40 antibodies and uses thereof
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
DK3307322T3
(en)
|
2015-09-04 |
2021-04-19 |
Primatope Therapeutics Inc |
Humanized anti-cd40 antibodies and uses thereof
|
BR112018006360A2
(en)
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
agonistic antibodies that specifically bind to human cd40 and methods of use
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017156349A1
(en)
|
2016-03-10 |
2017-09-14 |
Cold Genesys, Inc. |
Methods of treating solid or lymphatic tumors by combination therapy
|
EP3448260A4
(en)
|
2016-04-27 |
2019-10-09 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
TW201803905A
(en)
|
2016-06-20 |
2018-02-01 |
克馬伯有限公司 |
Multispecific antibodies for immuno-oncology
|
WO2018183041A1
(en)
|
2017-03-27 |
2018-10-04 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
JP7212138B2
(en)
*
|
2018-07-20 |
2023-01-24 |
ヨウキュア(ベイジン)バイオファーマ カンパニー リミテッド |
Anti-CD40 antibody and uses thereof
|
US20200190163A1
(en)
*
|
2018-10-26 |
2020-06-18 |
Lijun Wu |
Humanized bcma-car-t cells
|
US20230192840A1
(en)
*
|
2018-12-28 |
2023-06-22 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Antibody and use thereof
|
CN111454362B
(en)
*
|
2019-03-04 |
2021-03-02 |
北京天广实生物技术股份有限公司 |
Antibodies that specifically bind to CD40 and uses thereof
|
WO2021043206A1
(en)
*
|
2019-09-03 |
2021-03-11 |
百奥泰生物制药股份有限公司 |
Anti-tigit immunosuppressant and application thereof
|
CN113563473A
(en)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
Tetravalent bispecific antibody, preparation method and application thereof
|
CN111763259B
(en)
*
|
2020-09-03 |
2020-12-15 |
北京百奥赛图基因生物技术有限公司 |
anti-CD 40 antibodies and uses thereof
|
CN117500816A
(en)
|
2021-08-26 |
2024-02-02 |
映恩生物制药(苏州)有限公司 |
Steroid and conjugate thereof
|
WO2023044048A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Novartis Ag |
Methods for prevention of graft rejection in xenotransplantation
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|